Skip to content

Iterum Therapeutics (ITRM) Stock Jumps over 100% On Positive Pre-NDA Meeting

Sam Boughedda trader
Updated 30 Sep 2020

Practice Stock Trading
ITRM Iterum

Pharmaceutical company Iterum Therapeutics (NASDAQ: ITRM) has revealed its plan to proceed with a New Drug Application (NDA) for sulopenem etzadroxil/probenecid, a tablet, for the treatment of urinary tract infections.

The company said it had a positive pre-NDA meeting with the FDA and was pleased with how it went, stating that they believe they now have an understanding of the agency’s requirements for its submission.

Corey Fishman, Iterum Chief Executive Officer, said the company “have confidence in our decision to move forward with our NDA package for sulopenem etzadroxil/probenecid for the treatment of uUTI due to quinolone-resistant pathogens.

“We estimate that there are over 6 million quinolone-resistant urinary tract infections annually in the U.S., many of which are also multi-drug resistant, and sulopenem has demonstrated superiority versus ciprofloxacin in treating these infections.”

The news has resulted in a strong rally for Iterum’s stock price, moving from yesterday’s close of $0.64 to $1.32 per share after a 106% move.


Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.